ArticleCells2026

MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma.

María Labrador et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.